Article
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Nature medicine - 1 Aug 2015
Wilson Wyndham H, Young Ryan M, Schmitz Roland, Yang Yandan, Pittaluga Stefania, Wright George, Lih Chih-Jian, Williams P Mickey, Shaffer Arthur L, Gerecitano John, de Vos Sven, Goy Andre, Kenkre Vaishalee P, Barr Paul M, Blum Kristie A, Shustov Andrei, Advani Ranjana, Fowler Nathan H, Vose Julie M, Elstrom Rebecca L, Habermann Thomas M, Barrientos Jacqueline C, McGreivy Jesse, Fardis Maria, Chang Betty Y, Clow Fong, Munneke Brian, Moussa Davina, Beaupre Darrin M, Staudt Louis M
Abstract excerpt
The two major subtypes of diffuse large B cell lymphoma (DLBCL)--activated B cell-like (ABC) and germinal center B cell-like (GCB)--arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling. The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.